《美股》洛歇馬丁(LMT.US)收挫近11% 上季純利大跌79%兼降全年度盈利展望
美國軍工巨擘洛歇馬丁(LMT.US)截至6月29日止次季總銷售按年微升0.2%至181.55億美元,遜市場預期的185.7億美元。受累一項航天受機密項目帶來16億美元損失,季度純利按年大跌79.2%至3.42億美元,每股純利1.46美元。經調整每股純利7.29美元,好過市場預期的6.44美元。
洛歇馬丁降全年度盈利展望,經營溢利預測由4月時預測的介乎81億至82億美元,降至最新介乎66億至67億美元。
該股隔晚(22日)急跌10.8%收報410.74美元,盤後交易時段回升近1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.